Clinical Trial News and Research

RSS
TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Athera receives support from FP7 for development of fully human antibody PC-mAb

Athera receives support from FP7 for development of fully human antibody PC-mAb

FDA approves MENTOR MemoryShape Breast Implants

FDA approves MENTOR MemoryShape Breast Implants

Irene Pollin gifts $10 million to the Ciccarone Center for Prevention of Heart Disease

Irene Pollin gifts $10 million to the Ciccarone Center for Prevention of Heart Disease

Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Penn Medicine researchers identify key molecular player in recurrent breast cancer

Penn Medicine researchers identify key molecular player in recurrent breast cancer

NACC recommendations address established pain therapies and preview potential future advances

NACC recommendations address established pain therapies and preview potential future advances

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma announces closing of $15 million Series C financing

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Radionuclide drug treatment planning goes to next level with 3-D patient models

Radionuclide drug treatment planning goes to next level with 3-D patient models

Eribulin shows increased benefit among women sharing certain traits

Eribulin shows increased benefit among women sharing certain traits

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Mayo Clinic announces first US stem cell clinical trial for children with hypoplastic left heart syndrome

Mayo Clinic announces first US stem cell clinical trial for children with hypoplastic left heart syndrome

Massachusetts Eye and Ear enrolls deaf children in new clinical trial of Auditory Brainstem Implant

Massachusetts Eye and Ear enrolls deaf children in new clinical trial of Auditory Brainstem Implant

Countrywide study in Germany deems PRRT as life-prolonging treatment for patients with NETs

Countrywide study in Germany deems PRRT as life-prolonging treatment for patients with NETs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.